Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Anaesthesia ; 75(8): 1039-1049, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32342498

RESUMEN

In patients with pre-operative anaemia undergoing cardiac surgery, combination treatment with intravenous iron, subcutaneous erythropoietin alpha, vitamin B12 and oral folic acid reduces allogeneic blood product transfusions. It is unclear if certain types of anaemia particularly benefit from this treatment. We performed a post-hoc analysis of anaemic patients from a randomised trial on the 'Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery'. We used linear regression analyses to examine the efficacy of a combination anaemia treatment compared with placebo on the following deficiencies, each representing a part of the combination treatment: ferritin and transferrin saturation; endogenous erythropoietin; holotranscobalamine; and folic acid in erythrocytes. Efficacy was defined as change in reticulocyte count from baseline to the first, third and fifth postoperative days and represented erythropoietic activity in the immediate peri-operative recovery phase. In all 253 anaemic patients, iron deficiency was the most common cause of anaemia. Treatment significantly increased reticulocyte count in all regression analyses on postoperative days 1, 3 and 5 (all p < 0.001). Baseline ferritin and endogenous erythropoietin were negatively associated with change in reticulocyte count on postoperative day 5, with an unstandardised regression coefficient B of -0.08 (95%CI -0.14 to -0.02) and -0.14 (95%CI -0.23 to -0.06), respectively. Quadruple anaemia treatment was effective regardless of the cause of anaemia and its effect manifested early in the peri-operative recovery phase. The more pronounced a deficiency was, the stronger the subsequent boost to erythropoiesis may have been.


Asunto(s)
Anemia/tratamiento farmacológico , Cuidados Preoperatorios/métodos , Administración Intravenosa , Anciano , Anciano de 80 o más Años , Anemia Ferropénica/tratamiento farmacológico , Transfusión Sanguínea/estadística & datos numéricos , Procedimientos Quirúrgicos Cardíacos/métodos , Método Doble Ciego , Quimioterapia Combinada , Eritropoyetina/administración & dosificación , Eritropoyetina/uso terapéutico , Femenino , Ácido Fólico/administración & dosificación , Ácido Fólico/uso terapéutico , Hematínicos/administración & dosificación , Hematínicos/uso terapéutico , Humanos , Hierro/administración & dosificación , Hierro/uso terapéutico , Masculino , Persona de Mediana Edad , Periodo Posoperatorio , Recuento de Reticulocitos , Vitamina B 12/administración & dosificación , Vitamina B 12/uso terapéutico , Complejo Vitamínico B/administración & dosificación , Complejo Vitamínico B/uso terapéutico
3.
Audiol Neurootol ; 16(1): 36-40, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-20523038

RESUMEN

Patients with autoimmune inner ear disease develop rapidly progressive sensorineural hearing loss over a period of several weeks or months, often accompanied by vestibular loss. This disease can occur as a distinct clinical entity or in association with an underlying autoimmune disorder. Treatment comprises immunosuppression by corticosteroids, cytostatic drugs or tumor necrosis factor-α antagonists. We report histopathological and immunohistochemical findings of the inner ear of a patient with a granulomatous inner ear disease suffering from Crohn's disease that was nonresponsive to treatment and who underwent surgery for bilateral cochlear implants.


Asunto(s)
Enfermedades Autoinmunes/patología , Enfermedad de Crohn/patología , Enfermedades del Laberinto/patología , Adulto , Enfermedades Autoinmunes/tratamiento farmacológico , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/cirugía , Implantación Coclear , Implantes Cocleares , Enfermedad de Crohn/inmunología , Diagnóstico Diferencial , Humanos , Inmunohistoquímica , Enfermedades del Laberinto/tratamiento farmacológico , Enfermedades del Laberinto/inmunología , Enfermedades del Laberinto/cirugía , Masculino , Linfocitos T/inmunología , Linfocitos T/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA